ABHD17C, a metabolic and immune-related gene signature, predicts prognosis and anti-PD1 therapy response in pancreatic cancer.

ABSTRACT:

Background

PDAC is a highly malignant and immune-suppressive tumor, posing great challenges to therapy.

Methods

In this study, we utilized multi-center RNA sequencing and non-negative matrix factorization clustering (NMF) to identify a group of metabolism-related genes that could effectively predict the immune status and survival (both disease-free survival and overall survival) of pancreatic ductal adenocarcinoma (PDAC) patients. Subsequently, through the integration of single cell sequencing and our center's prospective and retrospective cohort studies, we identified ABHD17C, which possesses metabolic and immune-related characteristics, as a potential biomarker for predicting the prognosis and response to anti-PD1 therapy in PDAC. We then demonstrated how ABHD17C participa

SUBMITTER: Zhang W 

PROVIDER: S-EPMC10241759 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature